GlassScriptPhysician profile
Christopher D Sims
NPI 1386687457
$4,844.85
in general payments reported to CMS, 2019-2025
45 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $630 · 2021: $757 · 2022: $927 · 2023: $921 · 2024: $443 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.30 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $741.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $459.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $231.06 | 2019-2025 | |
| Amgen INC. | $157.25 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $155.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $154.39 | 2020-2025 | Breztri, Farxiga |
| Medtronic, INC. | $153.61 | 2023 | Minimed 780g, Minimed 770g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.20 | 2019-2024 | Jardiance |
| Supernus Pharmaceuticals, INC. | $140.92 | 2019-2022 | |
| Sobi, INC | $130.82 | 2019-2022 | |
| Shield Therapeutics INC | $114.81 | 2023-2024 | Accrufer |
| Agile Therapeutics, INC. | $109.48 | 2022-2023 | Twirla |
| Biogen, INC. | $106.21 | 2025 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $90.67 | 2024-2025 | Fanapt |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.